Opendata, web and dolomites

REUSE4MALARIA SIGNED

Drug Repurposing for Malaria Chemoprotection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "REUSE4MALARIA" data sheet

The following table provides information about the project.

Coordinator
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES 

Organization address
address: AVENIDA PROF EGAS MONIZ
city: LISBOA
postcode: 1649 028
website: www.imm.ul.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 145˙500 €
 EC max contribution 145˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2018-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES PT (LISBOA) coordinator 145˙500.00

Map

 Project objective

Malaria is a serious parasitic disease afflicting 198 million people in 2013, with an estimated death toll of approximately 600 000. Approximately half the world’s population is at risk of malaria. So far there is no cure/vaccine against malaria and current chemoprotective treatments have shortcomings, such as: 1) Limited Number of Drugs effective against malaria parasites; 2) Adverse Side Effects (observed in 32% to 44% of users); 3) Parasite Resistance to most of the drugs used for prevention and treatment; and 4) Limited Use (restrictions on age, genetic traits, pregnancy, etc). Our ERC-funded research uncovered a novel mechanism of action that can be targeted for malaria chemoprotection, with fewer side effects and reduced propensity to generate parasite resistance, on which we filed for IP protection. Furthermore, we have identified a set of likely drug candidates already validated in the clinic, which are likely candidates for malaria chemoprotection. In fact, our preliminary data indicates that a known anti-diabetic drug significantly affects parasite growth. We are seeking funding to initiate pre-clinical studies for repurposing this drug for malaria chemoprotection. This PoC funding will allow us to complete the following aims: 1) in vitro profiling to define therapeutic dose for malaria chemoprotection; 2) in vivo profiling to perform efficacy and toxicity studies; 3) further define IP Strategy; 4) draft early stage Regulatory Approval Roadmap; 5) conduct Market Analysis and develop a Business Case.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REUSE4MALARIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REUSE4MALARIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

REPLAY_DMN (2019)

A theory of global memory systems

Read More  

E-DIRECT (2020)

Evolution of Direct Reciprocity in Complex Environments

Read More  

HYDROGEN (2019)

HighlY performing proton exchange membrane water electrolysers with reinforceD membRanes fOr efficient hydrogen GENeration

Read More